Fingolimod in RRMS: Indication of added benefit in certain patients

July 03, 2015

Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed fingolimod (trade name: Gilenya), a drug for the treatment of adults with highly active relapsing remitting multiple sclerosis (RRMS). The Federal Joint Committee (G-BA) had limited its decision on the first assessment from 2012 to three years because it considered the certainty of the data as insufficient. This obliged the drug manufacturer to submit a second dossier.

It did not submit any new studies, but reanalysed studies that were already available. On this basis, IQWiG reached different conclusions: From the data, an added benefit was now derived for two instead of only one of a total of three patient groups. IQWiG now found an indication where it had found a hint before.

Indication instead of hint in severe course of disease

One study - the approval study TRANSFORMS - was decisive also for the new dossier assessment. The manufacturer presented new analyses with a more detailed differentiation between subgroups for two patient groups.

On the basis of the new analyses, there was an indication, and no longer a hint of an added benefit in patients with rapidly evolving severe RRMS. The extent of this added benefit depends on sex, however: It is considerable in women, and minor in men. While adverse events in the form of influenza-like symptoms are less frequent and certain adverse events (severe adverse events) occur more often in both sexes, only women have fewer relapses under fingolimod.

Added benefit for further patient group

The new analyses of TRANSFORMS showed that fingolimod has advantages for patients with highly active RRMS that has not been fully treated with interferon beta. In contrast, no added benefit had resulted from the first dossier.

Since both the annualized relapse rate is lower and adverse events in the form of influenza-like symptoms occur less frequently, IQWiG sees an indication of considerable added benefit in comparison with the appropriate comparator therapy.

Still no evaluable data for one group

However, also the new dossier contained no evaluable data for patients with highly active RRMS who have already received full previous treatment with interferon beta (IFN-β1a). The results of an indirect comparison again presented by the manufacturer are still unsuitable because the majority of the patients in the studies on the appropriate comparator therapy had not been fully pretreated.

Now added benefit for two thirds of the approval population

Overall, the current assessment showed an added benefit for approximately two thirds of all patients for whom fingolimod was approved in 2011. However, this assessment only referred to the therapeutic indication of the first approval from 2011, not to the indication "highly active RRMS with pretreatments other than interferon beta", which was also approved in 2014 and assessed according to AMNOG.

G-BA decides on the extent of added benefit

This dossier assessment is part of the early benefit assessment according to AMNOG supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
-end-
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language Information.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.

Institute for Quality and Efficiency in Health Care

Related Data Articles from Brightsurf:

Keep the data coming
A continuous data supply ensures data-intensive simulations can run at maximum speed.

Astronomers are bulging with data
For the first time, over 250 million stars in our galaxy's bulge have been surveyed in near-ultraviolet, optical, and near-infrared light, opening the door for astronomers to reexamine key questions about the Milky Way's formation and history.

Novel method for measuring spatial dependencies turns less data into more data
Researcher makes 'little data' act big through, the application of mathematical techniques normally used for time-series, to spatial processes.

Ups and downs in COVID-19 data may be caused by data reporting practices
As data accumulates on COVID-19 cases and deaths, researchers have observed patterns of peaks and valleys that repeat on a near-weekly basis.

Data centers use less energy than you think
Using the most detailed model to date of global data center energy use, researchers found that massive efficiency gains by data centers have kept energy use roughly flat over the past decade.

Storing data in music
Researchers at ETH Zurich have developed a technique for embedding data in music and transmitting it to a smartphone.

Life data economics: calling for new models to assess the value of human data
After the collapse of the blockchain bubble a number of research organisations are developing platforms to enable individual ownership of life data and establish the data valuation and pricing models.

Geoscience data group urges all scientific disciplines to make data open and accessible
Institutions, science funders, data repositories, publishers, researchers and scientific societies from all scientific disciplines must work together to ensure all scientific data are easy to find, access and use, according to a new commentary in Nature by members of the Enabling FAIR Data Steering Committee.

Democratizing data science
MIT researchers are hoping to advance the democratization of data science with a new tool for nonstatisticians that automatically generates models for analyzing raw data.

Getting the most out of atmospheric data analysis
An international team including researchers from Kanazawa University used a new approach to analyze an atmospheric data set spanning 18 years for the investigation of new-particle formation.

Read More: Data News and Data Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.